504 - Second cycle of catumaxomab treatment in patients with malignant ascites: results from the secimas study

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Clinical research
Supportive Measures
Basic Scientific Principles
Presenter Gülten Oskay-Özcelik
Authors G. Oskay-Özcelik1, I.B. Vergote2, A. Santoro3, F. Marmé4, P. Rosenberg5, J. Sehouli6
  • 1Praxis Hindenburg, 13595 - Berlin/DE
  • 2Obstetrics & Gynaecology, University Hospital Gasthuisberg, BE-3000 - Leuven/BE
  • 3Humanitas Cancer Center, Istituto Clinico Humanitas, IT-20089 - Rozzano/IT
  • 4Inf 460, Universitätsfrauenklinik Heidelberg & Nationales Centrum für Tumorerkrankungen (NCT), 69120 - Heidelberg/DE
  • 5Onkologiska Kliniken Universitetssjukhuset, University Hospital Linköping, Linköping/SE
  • 6Charite Medical University, 13353 - Berlin/DE



The SECIMAS study investigated the feasibility of a second cycle of 4 intra-peritoneal (i.p.) infusions of catumaxomab in patients who responded to treatment with 4 i.p. catumaxomab infusions in the CASIMAS study.

Patients and methods

Eligible patients had to have completed 4 i.p. prior infusions of catumaxomab in the CASIMAS study and required their first therapeutic puncture after > 60 days. Primary endpoint was the proportion of patients who were able to receive at least 3 infusions. Secondary endpoints were safety including a composite safety score (CSS) summarizing the worst CTCAE grades for the main TEAEs (pyrexia, nausea, vomiting, and abdominal pain) and the development of anti-drug antibodies (ADA). Efficacy endpoints were puncture-free survival (PuFS), time to puncture (TTPu) and overall survival (OS).


Eight of 9 selected patients from the CASIMAS study were treated with a 2nd of catumaxomab. Eight (100%) patients received all 4 infusions within 20 days, thus the primary endpoint was met with a high compliance rate. The median CSS was comparable for these 8 patients with 3.4 after the first cycle and 3.0 after the second cycle. Less patients in the SECIMAS study had AEs with CTC >3 (25%) compared to CASIMAS (70.1%). All 8 (100%) patients were ADA-positive at study entry and remained ADA-positive throughout treatment. PuFS was 47.5 days (28;181) and TTPu 60 days (34;na) after the 2nd cycle, while it was 37 days (24;61) and 102 days (69;159), respectively after the first cycle. OS was 406.5 days (281;480) in the SECIMAS study and 201 days (169;241) in the CASIMAS study.


The study demonstrates that despite the advanced stage of disease and the presence of ADA, a second cycle of i.p. catumaxomab treatment is feasible and well tolerated in selected patients suffering from malignant ascites and requiring treatment for ascites after a first cycle of catumaxomab. These patients actually seem to benefit from the second cycle catumaxomab in the same range as after the first cycle.


I.B. Vergote: consultant for Fresenius Biotech GmbH.

A. Santoro: financial support for Fresenius Biotech GmbH.

F. Marmé: financial support for clinical studies from Fresenius Biotech GmbH.

P. Rosenberg: financial support for clinical studies from Fresenius Biotech GmbH.

J. Sehouli: consultant for Fresenius Biotech GmbH and financial support for clinical studies.

All other authors have declared no conflicts of interest.